Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemotherapy With or Without Cemiplimab in Sinonasal Squamous Cell Carcinoma
NCT07281417Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2026
- Primary completion
- Dec 2030
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cemiplimab in sinonasal squamous cell carcinoma (SNSCC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Event Free Survival up to 5 years. Started Sep 2026; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
sinonasal squamous cell carcinoma (SNSCC)
Beyond the preview
Go deeper on NCT07281417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281417.